Allison Gartung

TL;DR: It is shown that tumor cells killed by chemotherapy or targeted therapy stimulate primary tumor growth when coinjected with a subthreshold (nontumorigenic) inoculum of tumor cells by triggering macrophage proinflammatory cytokine release after phosphatidylserine exposure.

TL;DR: Results indicate that PTUPB may act as a “surge protector” against therapy-induced protumorigenic mediators to improve patient survival by preventing tumor recurrence and combined pharmacological abrogation of the cyclooxygenase-2 and soluble epoxide hydrolase pathways prevented the debris-induced surge of both cytokines and lipid mediators by macrophages.

TL;DR: Preoperative administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival.

TL;DR: Data demonstrate that SphK1 is a critical mediator in lipolysis-triggered inflammation in adipocytes and provides a novel intervention for adipose inflammation and associated metabolic syndromes.

TL;DR: The data suggest that TNFα treatment activates autocrine S1P/S1P2 signaling, which subsequently activates NFκB and leads to the proinflammatory responses in endothelial cells.